AXSOME THERAPEUTICS, INC. (AXSM)

Every figure this model derived for AXSM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 700,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 319,850,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 656,569,000 AssetsCurrent 2026-06-30
current liabilities 460,446,000 LiabilitiesCurrent 2026-06-30
equity 83,304,000 StockholdersEquity 2026-06-30
interest expense 6,692,000 InterestExpense 2026-06-30
ocf -71,259,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 776,569,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 96,419,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AXSM on one particular measure came for.

RatioValue
cash operating margin-11.48
current ratio1.43
current ratio reported1.43
dilution pct3.83
fcf margin-9.27
growth cv1.0
interest cover-27.8
operating margin-23.96
owner earnings margin-21.68
revenue growth56.87
revenue growth per share51.09
rule of 4032.91
sbc pct revenue12.42

What to be careful about

What this model itself distrusts about AXSM's figures. Written by the derivation as it ran, not added afterwards.